This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kane, R. C. Articles by Pazdur, R. Search for Related Content PubMed PubMed Citation Articles by Kane, R. C. Articles by Pazdur, R.

Bortezomib for the Treatment of Mantle Cell Lymphoma

Authors' Affiliation: Division of Drug Oncology Products, Office of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland

Requests for reprints: Robert C. Kane, Division of Drug Oncology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Room 2109, Building 22, 10903 New Hampshire Avenue, Silver Spring, MD 20993-0002. Phone: 301-796-1384; E-mail: robert.kane{at}fda.hhs.gov.

Purpose: To describe the Food and Drug Administration review and marketing approval considerations for bortezomib (Velcade) for the treatment of patients with mantle cell lymphoma.

Experimental Design: Food and Drug Administration reviewed a multicenter study of bortezomib in 155 patients with progressive mantle cell lymphoma after at least one prior therapy.

Results: Seventy-seven percent were stage IV, and 75% had one or more extranodal sites of disease. Prior therapy included an anthracycline or mitoxantrone, cyclophosphamide, and rituximab. Median age was 65 years. All received bortezomib 1.3 mg/m² i.v. on days 1, 4, 8, and 11 of each 3-week cycle. The primary end point was response. Response and progression were determined by independent review of serial computed tomography scans using International Lymphoma Workshop Response Criteria. The overall response rate was 31%, including complete response (CR) plus CR unconfirmed (CRu) plus partial response; median response duration was 9.3 months. The CR plus CRu response rate was 8% with a median duration of 15.4 months. Adverse events were similar to those observed previously for bortezomib. The most commonly reported treatment-emergent adverse events were asthenia (72%), peripheral neuropathies (55%), constipation (50%), diarrhea (47%), nausea (44%), and anorexia (39%). The most common adverse event leading to discontinuation was neuropathy.

Conclusions: Bortezomib received regular approval for the treatment of patients with mantle cell lymphoma in relapse after prior therapy.

This article has been cited by other articles:

				J. S. Carew, S. T. Nawrocki, V. K. Reddy, D. Bush, J. E. Rehg, A. Goodwin, J. A. Houghton, R. A. Casero Jr, L. J. Marton, and J. L. Cleveland The Novel Polyamine Analogue CGC-11093 Enhances the Antimyeloma Activity of Bortezomib Cancer Res., June 15, 2008; 68(12): 4783 - 4790. [Abstract] [Full Text] [PDF]

				S. Michopoulos, K. Petraki, C. Matsouka, E. Kastritis, H. Chrysanthopoulou, and M. A. Dimopoulos Mantle-Cell Lymphoma (Multiple Lymphomatous Polyposis) of the Entire GI Tract J. Clin. Oncol., March 20, 2008; 26(9): 1555 - 1557. [Full Text] [PDF]